MedPath

Microfluidics Versus Density Gradient Centrifugation for Sperm Preparation in IVF

Not Applicable
Completed
Conditions
Male Infertility
Sperm DNA Fragmentation
In Vitro Fertilization (IVF)
Registration Number
NCT07004309
Lead Sponsor
Hanoi Medical University
Brief Summary

This randomized controlled trial aimed to compare the effectiveness of microfluidic sperm sorting and density gradient centrifugation (DGC) in reducing sperm DNA fragmentation index (DFI) and improving clinical outcomes in IVF. A total of 119 couples underwent IVF and were assigned to either microfluidic or DGC sperm preparation. The study evaluated sperm quality, fertilization, embryo development, and live birth rates.

Detailed Description

This single-center randomized controlled trial was conducted at Hanoi Medical University Hospital from March 2023 to March 2024. Couples undergoing IVF were randomized to two sperm preparation methods: microfluidics or density gradient centrifugation. Sperm DNA fragmentation index (DFI) was assessed before and after preparation. Primary outcomes included live birth rate and DFI reduction; secondary outcomes included sperm motility and morphology, fertilization rate, embryo quality, and pregnancy outcomes. The study received IRB approval and adhered to ethical standards.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
119
Inclusion Criteria
  • Female partner aged between 18 and 40 years
  • Couples undergoing in vitro fertilization (IVF) cycles at the IVF and Tissue Engineering Center, Hanoi Medical University, between January 2022 and January 2024
  • Use of autologous oocytes
  • Use of ejaculated sperm
  • Both partners provide written informed consent
Exclusion Criteria
  • Use of donor oocytes or donor sperm

  • Requirement for testicular sperm extraction

  • Diagnosis of oligoasthenozoospermia (OA) based on WHO 2021 criteria

  • Female partner classified as having poor ovarian prognosis according to the POSEIDON 2016 criteria, including:

    • Anti-Müllerian hormone (AMH) level < 1.2 ng/mL
    • Antral follicle count (AFC) < 5
    • Or history of poor ovarian response (≤9 oocytes retrieved in previous cycles)
  • Preimplantation genetic testing (PGT) cycles

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Sperm DNA Fragmentation Index (DFI)Day of oocyte retrieval

DFI measured before and after sperm preparation using SCSA method. Comparison between microfluidics and DGC groups

Live birth rateUp to 9 months after embryo transfer

Defined as the delivery of a live-born infant after 22 weeks of gestation. Comparison between microfluidics and DGC groups.

Secondary Outcome Measures
NameTimeMethod
Sperm motility after preparationImmediately after sperm preparation

Percentage of motile sperm, including both progressive and non-progressive motility, assessed post-preparation using WHO 2021 criteria.

Normal sperm morphologyImmediately after sperm preparation

Percentage of sperm with normal morphology after preparation, assessed using strict WHO 2021 criteria.

Fertilization rate17-20 hours after ICSI

Proportion of injected oocytes showing two pronuclei (2PN).

Good-quality embryo rate on Day 2Day 2 after fertilization

Percentage of embryos with 4-6 blastomeres and \<10% fragmentation on Day 2.

Biochemical pregnancy rate10-12 days after embryo transfer

Defined as serum β-hCG \>25 IU/L after embryo transfer.

Clinical pregnancy rate4 weeks after embryo transfer

Presence of gestational sac and fetal heartbeat confirmed on ultrasound.

Ongoing pregnancy rate12 weeks after embryo transfer

Viable intrauterine pregnancy confirmed by ultrasound at 12 weeks.

Trial Locations

Locations (1)

Center of IVF and Tissue Engineering, Hanoi Medical University Hospital

🇻🇳

Ha Noi, Vietnam

© Copyright 2025. All Rights Reserved by MedPath